Critically, with respect to B-cell malignancies, we observe an oncogenic function for hnRNP K. Our data showed that hnRNP K is overexpressed in DLBCL patients and higher expression of hnRNP K correlates with poor clinical outcomes and lack of response to chemotherapy in these patients. The gene discussed is HNRNPK; the disease is diffuse large B-cell lymphoma.